SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
3.960
+0.340 (9.39%)
May 13, 2026, 4:00 PM EDT - Market closed
SAB Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
86
Market Cap
278.29M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 1.32M | -916.58K | -40.94% |
| Dec 31, 2023 | 2.24M | -21.67M | -90.63% |
| Dec 31, 2022 | 23.90M | -36.97M | -60.73% |
| Dec 31, 2021 | 60.88M | 5.64M | 10.21% |
| Dec 31, 2020 | 55.24M | 51.80M | 1,504.91% |
| Dec 31, 2019 | 3.44M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Coherus Oncology | 46.88M |
| Fennec Pharmaceuticals | 44.64M |
| Voyager Therapeutics | 36.49M |
| Foghorn Therapeutics | 28.22M |
| LENZ Therapeutics | 20.99M |
| Adagene | 7.67M |
| Fate Therapeutics | 6.65M |
| Cartesian Therapeutics | 1.78M |
SABS News
- 1 day ago - SAB Biotherapeutics price target raised to $10 from $7 at H.C. Wainwright - TheFly
- 1 day ago - SAB Biotherapeutics Earnings Call Transcript: Q1 2026 - Transcripts
- 1 day ago - SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights - GlobeNewsWire
- 8 days ago - SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET - GlobeNewsWire
- 14 days ago - Emergent BioSolutions enters SAB-142 development pact with SAB Biotherapeutics - TheFly
- 21 days ago - SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026 - GlobeNewsWire
- 5 weeks ago - SAB Biotherapeutics initiated with a Buy at Rodman & Renshaw - TheFly
- 7 weeks ago - SAB BIO Announces Closing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire